OLUX E Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Olux E, and what generic alternatives are available?

Olux E is a drug marketed by Norvium Bioscience and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in OLUX E is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Olux E

A generic version of OLUX E was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for OLUX E?
What are the global sales for OLUX E?
What is Average Wholesale Price for OLUX E?

Summary for OLUX E

International Patents:	22
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	80
Patent Applications:	4,476
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLUX E
DailyMed Link:	OLUX E at DailyMed

Drug patent expirations by year for OLUX E

Paragraph IV (Patent) Challenges for OLUX E

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUX E	Emulsion Foam	clobetasol propionate	0.05%	022013	1	2010-02-25

US Patents and Regulatory Information for OLUX E

OLUX E is protected by two US patents.

Patents protecting OLUX E

Microemulsion process and composition
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES

Microemulsion and sub-micron emulsion process and compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norvium Bioscience	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Norvium Bioscience	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for OLUX E

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	⤷ Sign Up	⤷ Sign Up
Norvium Bioscience	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for OLUX E

See the table below for patents covering OLUX E around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	0015193		⤷ Sign Up
Australia	2006253913	Vitamin formulation	⤷ Sign Up
New Zealand	508259	Mousse composition	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for OLUX E

Paragraph IV (Patent) Challenges for OLUX E

Patents protecting OLUX E

Make Better Decisions: Try a trial or see plans & pricing